Παρασκευή 5 Ιανουαρίου 2018

Drug Combination Improves Outlook for Some Patients with Chronic Lymphocytic Leukemia

Interim results from an ongoing clinical trial show that patients with relapsed or refractory chronic lymphocytic leukemia treated with rituximab plus venetoclax have longer progression-free survival compared with patients treated with chemotherapy.



http://ift.tt/2qy3oc4

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου